India Pharma Outlook Team | Monday, 25 August 2025
GSK has announced the launch of its long-awaited advanced therapies, Jemperli (dostarlimab) and Zejula (niraparib) in India today, recognizing the need for access to advanced therapies to support cancer care.
Gynaecological cancers are amongst the most Common cancers in women in India, with increasing incidence rates. Endometrial and ovarian cancers are in fact rightly acknowledged as two of the top three gynecological cancers in India. From the current incidence rates, endometrial and ovarian cancer in India is projected to increase in incidence rates by 78% and 69 % respectively by 2045.
A cancer that develops from the endometrium, the uterine lining, is known as endometrial cancer. In India, around one-fourth of individuals with endometrial cancer had the disease at an advanced stage. Chemotherapy is still a common treatment at this point, but it frequently has negative long-term effects and is toxic.
For the second-line treatment of advanced or recurrent endometrial cancer that is mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H), Jemperli is the first and only PD-1 immunotherapy that has been approved in India. Jemperli functions by inhibiting the PD-1 pathway, which cancer cells utilize to avoid immune system recognition. This makes it easier for immune cells to identify and combat the tumor.
Also Read: Glenmark Introduces Tevimbra in India for Advanced Cancer Care
The GARNET trial provided scientific proof of Jemperli's effectiveness in treating patients with advanced or recurrent dMMR/MSI-H endometrial cancer. With an estimated probability of continued response of 93.3% and 83.7% at 12 and 24 months, respectively, the study showed that Jemperli achieved an objective response rate of 45.5%10.
These results, when paired with a tolerable safety profile, demonstrate the possibility of long-lasting clinical benefits in a group where conventional chemotherapy has traditionally provided poor long-term results and limited efficacy.
